Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1.
In this study, we evaluated baseline susceptibility to bevirimat (BVM), the first in a new class of antiretroviral agents, maturation inhibitors. We evaluated susceptibility to BVM by complete gag genotypic and phenotypic testing of 20 patient-derived human immunodeficiency virus type 1 isolates and 20 site-directed mutants. We found that reduced BVM susceptibility was associated with naturally occurring polymorphisms at positions 6, 7, and 8 in Gag spacer peptide 1.
Van Baelen
Kurt
K
Virco BVBA, Generaal De Wittelaan L11 B3, 2800 Mechelen, Belgium. kvbaele1@its.jnj.com
Salzwedel
Karl
K
Rondelez
Evelien
E
Van Eygen
Veerle
V
De Vos
Stephanie
S
Verheyen
Ann
A
Steegen
Kim
K
Verlinden
Yvan
Y
Allaway
Graham P
GP
Stuyver
Lieven J
LJ
D000595:Amino Acid Sequence; D019380:Anti-HIV Agents / Q000494:pharmacology*; D005838:Genotype; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods; D016297:Mutagenesis, Site-Directed; D009154:Mutation; D010455:Peptides / Q000235:genetics; D010641:Phenotype; D011110:Polymorphism, Genetic; D016415:Sequence Alignment; D013386:Succinates / Q000494:pharmacology*; D014315:Triterpenes / Q000494:pharmacology*; D054301:gag Gene Products, Human Immunodeficiency Virus / Q000737:chemistry / Q000235:genetics*; D053978:Pentacyclic Triterpenes
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D010455:Peptides; D013386:Succinates; D014315:Triterpenes; D054301:gag Gene Products, Human Immunodeficiency Virus; C479935:bevirimat; D053978:Pentacyclic Triterpenes